Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Consolidated Statements of Operations
Net Revenues	$ 54,521	$ 49,774
Operating Expenses
Cost of sales (excluding depreciation and amortization)	19,985	21,804
Research and development	2,968	6,344
Selling, general, and administrative	17,587	13,683
Depreciation and amortization	10,898	11,183
Cortrophin pre-launch charges	38	4,602
Total Operating Expenses	51,476	57,616
Operating Income/(Loss)	3,045	(7,842)
Other Expense, net
Interest expense, net	(2,454)	(2,032)
Other (expense)/income, net	(515)	10
Income/(Loss) Before Benefit for Income Taxes	76	(9,864)
Benefit for income taxes	10	2,853
Net Income/(Loss)	$ 86	$ (7,011)
Basic and Diluted Earnings/(Loss) Per Share:
Basic Earnings/(Loss) Per Share	$ 0.01	$ (0.59)
Diluted Earnings/(Loss) Per Share	$ 0.01	$ (0.59)
Basic Weighted-Average Shares Outstanding	12,004	11,902
Diluted Weighted-Average Shares Outstanding	12,017	11,902